Arg1178
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg1178  -  SRC-3 (mouse)

Site Information
TNTPKQLrMQLQQrL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2363405

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Relevant cell line - cell type - tissue:
brain ( 1 , 4 , 5 , 6 , 7 ) , embryo ( 1 , 2 , 3 , 8 , 9 , 10 , 11 ) , MEF (fibroblast) ( 12 , 13 )

References 

1

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

2

Mulhern D (2012) CST Curation Set: 15845; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

3

Mulhern D (2012) CST Curation Set: 15846; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

4

Guo A (2012) CST Curation Set: 14306; Year: 2012; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

5

Guo A (2012) CST Curation Set: 14307; Year: 2012; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Guo A (2012) CST Curation Set: 14310; Year: 2012; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Guo A (2012) CST Curation Set: 14311; Year: 2012; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Guo A (2012) CST Curation Set: 14308; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

Guo A (2012) CST Curation Set: 14309; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

10

Guo A (2012) CST Curation Set: 14312; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

11

Guo A (2012) CST Curation Set: 14313; Year: 2012; Biosample/Treatment: tissue, embryo/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

12

Zhou J (2009) CST Curation Set: 6534; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

13

Zhou J (2009) CST Curation Set: 6533; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

14

Naeem H, et al. (2007) The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation. Mol Cell Biol 27, 120-34
17043108   Curated Info